NASDAQ:PLSE

Pulse Biosciences Stock Forecast, Price & News

$20.84
-0.93 (-4.27 %)
(As of 04/16/2021 11:01 AM ET)
Add
Compare
Today's Range
$20.84
Now: $20.84
$21.81
50-Day Range
$21.34
MA: $25.30
$31.90
52-Week Range
$6.21
Now: $20.84
$45.82
Volume232 shs
Average Volume142,790 shs
Market Capitalization$543.65 million
P/E RatioN/A
Dividend YieldN/A
Beta1.88
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue primarily for dermatology applications by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Hayward, California.
Pulse Biosciences logo

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PLSE
CUSIPN/A
Phone510-906-4600
Employees95
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.48 per share

Profitability

Net Income$-46,970,000.00

Miscellaneous

Market Cap$543.65 million
Next Earnings Date5/10/2021 (Estimated)
OptionableOptionable

Headlines

Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down to $22.88
April 8, 2021 |  americanbankingnews.com
Pulse Biosciences (NASDAQ:PLSE) Shares Gap Down to $23.09
March 29, 2021 |  americanbankingnews.com
Pulse Biosciences, Inc. Announces Redemption of Warrants
January 5, 2021 |  finance.yahoo.com
News for Pulse Biosciences Inc
December 5, 2020 |  markets.businessinsider.com
See More Headlines

MarketRank

Overall MarketRank

1.53 out of 5 stars

Medical Sector

470th out of 2,021 stocks

Surgical & Medical Instruments Industry

37th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.6 5 -4 -3 -2 -1 -
$20.84
-0.93 (-4.27 %)
(As of 04/16/2021 11:01 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PLSE News and Ratings via Email

Sign-up to receive the latest news and ratings for PLSE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Pulse Biosciences (NASDAQ:PLSE) Frequently Asked Questions

Is Pulse Biosciences a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Pulse Biosciences in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Pulse Biosciences stock.
View analyst ratings for Pulse Biosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Pulse Biosciences?

Wall Street analysts have given Pulse Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Pulse Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Pulse Biosciences' next earnings date?

Pulse Biosciences is scheduled to release its next quarterly earnings announcement on Monday, May 10th 2021.
View our earnings forecast for Pulse Biosciences
.

How were Pulse Biosciences' earnings last quarter?

Pulse Biosciences, Inc. (NASDAQ:PLSE) announced its quarterly earnings data on Sunday, February, 21st. The company reported ($0.54) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.45) by $0.09.
View Pulse Biosciences' earnings history
.

How has Pulse Biosciences' stock been impacted by Coronavirus (COVID-19)?

Pulse Biosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, PLSE shares have increased by 227.7% and is now trading at $20.84.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PLSE?

2 equities research analysts have issued twelve-month target prices for Pulse Biosciences' shares. Their forecasts range from $40.00 to $46.00. On average, they anticipate Pulse Biosciences' share price to reach $43.00 in the next twelve months. This suggests a possible upside of 106.3% from the stock's current price.
View analysts' price targets for Pulse Biosciences
or view top-rated stocks among Wall Street analysts.

Who are Pulse Biosciences' key executives?

Pulse Biosciences' management team includes the following people:
  • Mr. Darrin R. Uecker, Pres, CEO & Director (Age 55, Pay $1.42M)
  • Ms. Sandra A. Gardiner, Exec. VP of Fin. & Admin., CFO, Sec. and Treasurer (Age 55, Pay $90.26k)
  • Mr. Edward A. Ebbers, Exec. VP & GM of Dermatology (Age 61, Pay $419.85k)
  • Dr. Richard Nuccitelli Ph.D., Chief Science Officer
  • Dr. Holly Hartman Ph.D., J.D., VP of Bus. Devel. & Corp. Strategy
  • Ms. Patty Perla, VP of HR

What is Darrin R. Uecker's approval rating as Pulse Biosciences' CEO?

2 employees have rated Pulse Biosciences CEO Darrin R. Uecker on Glassdoor.com. Darrin R. Uecker has an approval rating of 100% among Pulse Biosciences' employees. This puts Darrin R. Uecker in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Pulse Biosciences' key competitors?

What other stocks do shareholders of Pulse Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pulse Biosciences investors own include Advanced Micro Devices (AMD), AbbVie (ABBV), Bausch Health Companies (BHC), Wayfair (W), Achaogen (AKAO), NVIDIA (NVDA), Portola Pharmaceuticals (PTLA), (CGC), Enphase Energy (ENPH) and Novavax (NVAX).

When did Pulse Biosciences IPO?

(PLSE) raised $20 million in an initial public offering (IPO) on Wednesday, May 18th 2016. The company issued 5,000,000 shares at a price of $4.00 per share. MDB Capital Group and Feltl and Company served as the underwriters for the IPO.

What is Pulse Biosciences' stock symbol?

Pulse Biosciences trades on the NASDAQ under the ticker symbol "PLSE."

Who are Pulse Biosciences' major shareholders?

Pulse Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Westside Investment Management Inc. (0.12%).
View institutional ownership trends for Pulse Biosciences
.

Which major investors are buying Pulse Biosciences stock?

PLSE stock was acquired by a variety of institutional investors in the last quarter, including Westside Investment Management Inc..
View insider buying and selling activity for Pulse Biosciences
or or view top insider-buying stocks.

How do I buy shares of Pulse Biosciences?

Shares of PLSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Pulse Biosciences' stock price today?

One share of PLSE stock can currently be purchased for approximately $20.84.

How much money does Pulse Biosciences make?

Pulse Biosciences has a market capitalization of $543.65 million. The company earns $-46,970,000.00 in net income (profit) each year or ($2.26) on an earnings per share basis.

How many employees does Pulse Biosciences have?

Pulse Biosciences employs 95 workers across the globe.

What is Pulse Biosciences' official website?

The official website for Pulse Biosciences is www.pulsebiosciences.com.

Where are Pulse Biosciences' headquarters?

Pulse Biosciences is headquartered at 3957 POINT EDEN WAY, HAYWARD CA, 94545.

How can I contact Pulse Biosciences?

Pulse Biosciences' mailing address is 3957 POINT EDEN WAY, HAYWARD CA, 94545. The company can be reached via phone at 510-906-4600 or via email at [email protected]


This page was last updated on 4/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.